The stock price of SELLAS Life Sciences Group Inc (NASDAQ: SLS) has surged by 5.84 when compared to previous closing price of 1.54, but the company has seen a 19.85% gain in its stock price over the last five trading sessions. Seeking Alpha reported 2024-04-19 that SELLAS Life Sciences Group, Inc. is a late-stage biotech company with a leading drug candidate, Galinpepimut-S, or GPS, that has a 44% probability of success and a potential 9x return. GPS is an immunotherapy drug targeting the Wilms Tumor 1 antigen, which is overexpressed in AML patients. The AML market size is estimated to be $3.1 billion. The upcoming interim readout of the GPS phase 3 clinical trial in April could significantly impact the valuation of the drug, with a successful trial potentially increasing its value to $1.5B.
Is It Worth Investing in SELLAS Life Sciences Group Inc (NASDAQ: SLS) Right Now?
Additionally, the 36-month beta value for SLS is 2.15. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for SLS is 55.88M and currently, short sellers hold a 9.43% ratio of that float. The average trading volume of SLS on April 24, 2024 was 1.42M shares.
SLS’s Market Performance
The stock of SELLAS Life Sciences Group Inc (SLS) has seen a 19.85% increase in the past week, with a 52.34% rise in the past month, and a 215.22% gain in the past quarter. The volatility ratio for the week is 10.42%, and the volatility levels for the past 30 days are at 10.29% for SLS. The simple moving average for the last 20 days is 25.36% for SLS stock, with a simple moving average of 38.24% for the last 200 days.
Analysts’ Opinion of SLS
Many brokerage firms have already submitted their reports for SLS stocks, with Cantor Fitzgerald repeating the rating for SLS by listing it as a “Overweight.” The predicted price for SLS in the upcoming period, according to Cantor Fitzgerald is $18 based on the research report published on July 21, 2021 of the previous year 2021.
H.C. Wainwright gave a rating of “Buy” to SLS, setting the target price at $11 in the report published on April 02nd of the previous year.
SLS Trading at 43.06% from the 50-Day Moving Average
After a stumble in the market that brought SLS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -14.84% of loss for the given period.
Volatility was left at 10.29%, however, over the last 30 days, the volatility rate increased by 10.42%, as shares surge +56.73% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +109.65% upper at present.
During the last 5 trading sessions, SLS rose by +19.85%, which changed the moving average for the period of 200-days by -0.61% in comparison to the 20-day moving average, which settled at $1.3297. In addition, SELLAS Life Sciences Group Inc saw 53.77% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for SLS
The total capital return value is set at 3.88. Equity return is now at value -874.00, with -271.27 for asset returns.
Based on SELLAS Life Sciences Group Inc (SLS), the company’s capital structure generated -0.13 points at debt to capital in total, while cash flow to debt ratio is standing at -34.67. The debt to equity ratio resting at -0.11. The interest coverage ratio of the stock is 154.42.
Currently, EBITDA for the company is -37.87 million with net debt to EBITDA at 0.06. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.23.
Conclusion
In conclusion, SELLAS Life Sciences Group Inc (SLS) has seen better performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
